Total Valuation
Reyon Pharmaceutical Co., Ltd. has a market cap or net worth of ₩181.76B. The enterprise value is ―.
Market Cap₩181.76B
Enterprise Value―
Share Statistics
Reyon Pharmaceutical Co., Ltd. has 18,586,811 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding18,586,811
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Reyon Pharmaceutical Co., Ltd.’s return on equity (ROE) is -0.14 and return on invested capital (ROIC) is -7.20%.
Return on Equity (ROE)-0.14
Return on Assets (ROA)-0.06
Return on Invested Capital (ROIC)-7.20%
Return on Capital Employed (ROCE)-0.10
Revenue Per Employee325.73M
Profits Per Employee-66.57M
Employee Count448
Asset Turnover0.31
Inventory Turnover2.96
Valuation Ratios
The current PE Ratio of Reyon Pharmaceutical Co., Ltd. is ―. Reyon Pharmaceutical Co., Ltd.’s PEG ratio is 0.00830.
PE Ratio―
PS Ratio1.37
PB Ratio0.91
Price to Fair Value0.91
Price to FCF-29.97
Price to Operating Cash Flow-51.20
PEG Ratio0.00830
Income Statement
In the last 12 months, Reyon Pharmaceutical Co., Ltd. had revenue of 145.93B and earned -29.83B in profits. Earnings per share was -1.60K.
Revenue145.93B
Gross Profit33.76B
Operating Income-31.57B
Pretax Income-24.67B
Net Income-29.83B
EBITDA228.10M
Earnings Per Share (EPS)-1.60K
Cash Flow
In the last 12 months, operating cash flow was -3.55B and capital expenditures -4.85B, giving a free cash flow of -8.40B billion.
Operating Cash Flow-3.55B
Free Cash Flow-8.40B
Free Cash Flow per Share-451.95
Dividends & Yields
Reyon Pharmaceutical Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.21
52-Week Price Change-12.22%
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)53.85K
Important Dates
Reyon Pharmaceutical Co., Ltd. upcoming earnings date is Aug 18, 2026, TBA (Confirmed).
Last Earnings DateMay 15, 2026
Next Earnings DateAug 18, 2026
Ex-Dividend Date―
Financial Position
Reyon Pharmaceutical Co., Ltd. as a current ratio of 0.56, with Debt / Equity ratio of 104.58%
Current Ratio0.56
Quick Ratio0.29
Debt to Market Cap1.07
Net Debt to EBITDA918.23
Interest Coverage Ratio-2.39
Taxes
In the past 12 months, Reyon Pharmaceutical Co., Ltd. has paid 5.02B in taxes.
Income Tax5.02B
Effective Tax Rate-0.20
Enterprise Valuation
Reyon Pharmaceutical Co., Ltd. EV to EBITDA ratio is 1.80K, with an EV/FCF ratio of -61.29.
EV to Sales2.81
EV to EBITDA1.80K
EV to Free Cash Flow-61.29
EV to Operating Cash Flow333.45
Balance Sheet
Reyon Pharmaceutical Co., Ltd. has ₩4.35B in cash and marketable securities with ₩219.17B in debt, giving a net cash position of -₩214.82B billion.
Cash & Marketable Securities₩4.35B
Total Debt₩219.17B
Net Cash-₩214.82B
Net Cash Per Share-₩11.56K
Tangible Book Value Per Share₩11.61K
Margins
Gross margin is 19.72%, with operating margin of -21.63%, and net profit margin of -20.44%.
Gross Margin19.72%
Operating Margin-21.63%
Pretax Margin-16.90%
Net Profit Margin-20.44%
EBITDA Margin0.16%
EBIT Margin-21.63%
Analyst Forecast
The average price target for Reyon Pharmaceutical Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-1.91%
EPS Growth Forecast-1104.32%